Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06310746
Other study ID # HLX6018-FIH101
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date April 23, 2024
Est. completion date December 30, 2026

Study information

Verified date June 2024
Source Shanghai Henlius Biotech
Contact Yanhua Ding
Email dingyanhua2003@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the safety, PK, and immunogenicity of a single intravenous administration of HLX6018 in healthy subjects, based on the preliminary efficacy and safety established through in vitro and in vivo experiments. This is a randomized, double-blind, placebo-controlled study with single dose escalation design to assess the safety, PK, and immunogenicity of HLX6018 in healthy subjects. It is planned to enroll 8-10 subjects in each of seven dose groups (0.25 mg/kg, 1.0 mg/kg, 4.0 mg/kg, 12 mg/kg, 25 mg/kg, 50 mg/kg, and 70 mg/kg). This is the first-in-human study of the investigational product.


Recruitment information / eligibility

Status Recruiting
Enrollment 66
Est. completion date December 30, 2026
Est. primary completion date December 30, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Fully informed about the nature, significance, potential inconveniences, and associated risks of the study prior to enrollment. Comprehend the study's procedures and methodology, agree to follow the clinical study protocol, and give voluntary written informed consent; 2. 18-55 years old, including the boundary value, male or female; 3. Body weight: 45-85 kg for females and 50-85 kg for males, including the boundary value; body mass index (BMI): 18.0-28.0 kg/m2 , including the boundary value, (BMI = body weight (kg)/body height2 (m2)); 4. Subjects, including males, must have no childbearing plan and take effective contraceptive measures from the time of informed consent to 6 months after the administration of the study drug. 5. Physical examinations and vital signs should be normal or abnormal without clinical significance. Exclusion Criteria: 1. Any clinically significant laboratory test abnormalities or, within 12 months before screening, any other clinically significant clinical findings indicative of diseases, including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, oncological, pulmonary, immunological, psychiatric, or cardiovascular conditions; 2. Donation/loss of = 450 mL of blood or receipt of blood transfusion or use of blood products within 3 months prior to screening, or planning to donate blood during the study or within 1 month after the end of the study; 3. Patients with severe trauma or major surgery within 3 months before screening, or planning to undergo surgery during the study; 4. Patients who smoke more than 5 cigarettes per day in the 3 months before screening; 5. History of drug abuse or addiction or alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine);

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
GARP/TGF-ß1 monoclonal antibody
It is planned to enroll 8-10 subjects in each of seven dose groups (0.25 mg/kg, 1.0 mg/kg, 4.0 mg/kg, 12 mg/kg, 25 mg/kg, 50 mg/kg, and 70 mg/kg).
Placebo
It is planned to enroll 8-10 subjects in each of seven dose groups (0.25 mg/kg, 1.0 mg/kg, 4.0 mg/kg, 12 mg/kg, 25 mg/kg, 50 mg/kg, and 70 mg/kg).

Locations

Country Name City State
China First Hospital of Jilin University Changchun Jilin

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Henlius Biotech

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The number of subjects experiencing adverse events (AEs) and serious adverse events (SAEs) Safety evaluation 0 to Day 99
Secondary AUC0-inf Area under the serum concentration-time curve 0 to Day 99
Secondary Cmax Peak concentration 0 to Day 99
Secondary Tmax Time to reach peak concentration 0 to Day 99
Secondary T1/2 Terminal elimination half-life 0 to Day 99
Secondary CL Clearance 0 to Day 99
Secondary ?z Terminal elimination rate constant 0 to Day 99
See also
  Status Clinical Trial Phase
Recruiting NCT05570058 - Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT02807025 - Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases N/A
Recruiting NCT05895565 - A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects Phase 1
Completed NCT03211507 - Idiopathic Pulmonary Fibrosis Job Exposures Study
Completed NCT02503657 - Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Recruiting NCT03873298 - Inhaled NO in IPF and COPD During 6 Minute Walk Test Phase 2
Terminated NCT03864328 - A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF Phase 2
Completed NCT05803850 - A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058 Phase 1
Withdrawn NCT05349760 - A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis Phase 2
Completed NCT01266317 - Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations Phase 1/Phase 2
Recruiting NCT05147597 - Turkish Validity and Reliability of SGRQ-I
Completed NCT04503044 - ILAs in CT Lung Cancer Screening Population
Recruiting NCT04564183 - Advancing Prevention of Pulmonary Fibrosis
Recruiting NCT05190211 - Telerehabilitation in Patients With Idiopathic Pulmonary Fibrosis N/A
Recruiting NCT04263727 - A Study of Patients With Chronic Disease
Completed NCT05353556 - Effects of Home-based Inspiratory Muscle Training in Patients With IPF N/A
Completed NCT02976935 - Functional MR Lung Imaging Using Hyperpolarised 129Xe
Recruiting NCT05193136 - Sleep Hygiene, Sarcopenia, and Cognitive Function in Respiratory Disease
Recruiting NCT06181370 - Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF Phase 1
Not yet recruiting NCT02885961 - The Coagulation Cascade in Idiopathic Pulmonary Fibrosis N/A